PTC Therapeutics, Inc. Debt Securities, Held-to-maturity, Unrealized Loss Position, Fair Value
PTC Therapeutics, Inc. (PTCT) had Debt Securities, Held-to-maturity, Unrealized Loss Position, Fair Value of $9.20 million as of 2020-06-30, per its 10-Q filed 2020-08-05.
Discontinued › Notes › Credit Losses › ASU 2016-13 Transition
us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionFairValue · last filed 2020-08-05
- 2020-06-30: Debt Securities, Held-to-maturity, Unrealized Loss Position, Fair Value $9.20M.
- 2020-03-31: Debt Securities, Held-to-maturity, Unrealized Loss Position, Fair Value $207.62M.
- 2019-12-31: Debt Securities, Held-to-maturity, Unrealized Loss Position, Fair Value $95.99M.
- 2019-09-30: Debt Securities, Held-to-maturity, Unrealized Loss Position, Fair Value $3.02M.
| Period end | Debt Securities, Held-to-maturity, Unrealized Loss Position, Fair Value |
|---|---|
| 2020-06-30 | $9.20M 10-Q · filed 2020-08-05 |
| 2020-03-31 | $207.62M 10-Q · filed 2020-04-30 |
| 2019-12-31 | $95.99M 10-Q · filed 2020-08-05 |
| 2019-09-30 | $3.02M 10-Q · filed 2019-10-30 |
| 2019-06-30 | $17.68M 10-Q · filed 2019-08-06 |
| 2019-03-31 | $67.79M 10-Q · filed 2019-05-02 |
| 2018-12-31 | $26.31M 10-Q · filed 2019-10-30 |
| 2018-09-30 | $36.50M 10-Q · filed 2018-11-05 |
| 2018-06-30 | $56.45M 10-Q · filed 2018-08-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |